rFVIII: Clinical Trials

7 trials of rFVIII, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 recruiting. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 4, Recruiting 1
Phase 21Terminated 1

Follow rFVIII: new trials by email Literature Review of rFVIII trials Research Report on rFVIII

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
VONVENDI, ADVATE - Von Willebrand Disease (VWD)
Phase 3RecruitingTakeda202025-10-132026-01-08
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
rVWF, rFVIII - Von Willebrand Disease (VWD)
Phase 3CompletedBaxalta now part of Shire382019-04-012025-09-03
rVWF IN PROPHYLAXIS
von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant) - Von Willebrand Disease
Phase 3CompletedTakeda292017-11-162021-08-06
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Vonicog alfa, Antihemophilic Factor (Recombinant) - Von Willebrand Disease
Phase 3CompletedBaxalta now part of Shire472017-11-062026-05-15
Weight-based Dosing in Hemophilia A
rFVIII - Hemophilia
Phase 2TerminatedCraig Seaman302015-09-012020-09-25
Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products - Hemophilia A, Hemophilia B
TerminatedBioverativ Therapeutics Inc.32015-07-012020-12-19
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII) - Von Willebrand Disease
Phase 3CompletedBaxalta now part of Shire492011-11-012021-05-19

Conditions studied

von Willebrand Diseases (5)  ·  Hemophilia A (2)  ·  Hemophilia B (1)

Sponsors

Baxalta now part of Shire (3)  ·  Takeda (2)  ·  Bioverativ Therapeutics Inc. (1)  ·  Craig Seaman (1)

Countries

United States (6)  ·  Germany (4)  ·  Italy (4)  ·  Netherlands (4)  ·  Russia (4)  ·  Spain (4)  ·  Austria (3)  ·  France (3)  ·  Turkey (Türkiye) (3)  ·  Belgium (2)  ·  Canada (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  China (1)

Top investigators

Craig Seaman, MD, MS (1)

Results publications

PMID 26239086, PMID 35439298, PMID 36861346

NIH funding

2016 (2), 2018 (1), 2023 (1)